Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ibrutinib-venetoclax produces high MRD-negative rates in CLL/SLL

Publish date:: June 23, 2020

Key clinical point: Ibrutinib-venetoclax appears to be an effective first-line therapy for CLL/SLL.

Major finding: 75% of patients were MRD-negative in peripheral blood, and 68% in bone marrow in an intention-to-treat analysis.

Study details: Open-label portion of a phase 2 trial of 164 patients with untreated CLL/SLL.

Disclosures: Dr. Siddiqi disclosed research funding and speakers bureau activity for Pharmacyclics, which sponsored the study, and others, as well as consulting/advising for several companies. Dr. Coombs disclosed consulting for AbbVie.

Citation:

Siddiqi T et al. EHA25. Abstract S158.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CLL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia,

Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients,

Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL,

Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies,